DOC2A: A Potential Drug Target and Biomarker (G8448)

Target Name: DOC2A

NCBI ID: G8448

DOC2A

DOC2A: A Potential Drug Target and Biomarker

DOC2A, short for doublecortin-伪, is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the doublecortin family, which includes several related proteins that share similar molecular structures and functions. One of the functions of DOC2A is to regulate the growth and differentiation of various cell types, including neurons and cancer cells. This protein has also been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, DOC2A has potential as a drug target or biomarker.

DOC2A as a Drug Target

DOC2A has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the ways that DOC2A contributes to these diseases is by regulating the growth and differentiation of cells that are prone to errors in their gene expression. Studies have shown that DOC2A can cause cells to undergo various changes in their gene expression patterns, including upregulating the expression of genes involved in cell growth and survival, and downregulating the expression of genes involved in cell death and differentiation.

In addition, DOC2A has also been shown to contribute to the development of cancer. For example, DOC2A has been shown to promote the growth and survival of various cancer cells, and it has been shown to play a role in the development of neuroendocrine tumors. Additionally, DOC2A has also been shown to contribute to the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

DOC2A as a Biomarker

DOC2A has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the ways that DOC2A can be used as a biomarker is by measuring the levels of DOC2A in various body tissues or fluids, such as blood, saliva, or urine. Studies have shown that the levels of DOC2A can vary significantly depending on the level of the disease, and that DOC2A levels may be useful as a biomarker for certain diseases.

For example, DOC2A has been shown to be upregulated in various body tissues and fluids associated with cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, studies have shown that the levels of DOC2A in these tissues and fluids can be used as a biomarker for disease progression and response to therapy.

Conclusion

In conclusion, DOC2A is a protein that has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, DOC2A has potential as a drug target or biomarker. Further research is needed to fully understand the role of DOC2A in these diseases, and to determine the most effective way to use it as a therapeutic tool.

Protein Name: Double C2 Domain Alpha

Functions: Calcium sensor which most probably regulates fusion of vesicles with membranes. Binds calcium and phospholipids. May be involved in calcium dependent neurotransmitter release through the interaction with UNC13A. May be involved in calcium-dependent spontaneous release of neurotransmitter in absence of action potentials in neuronal cells. Regulates Ca(2+)-dependent secretory lysosome exocytosis in mast cells

The "DOC2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DOC2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets